MAAT PHARMA SACA
COMM · CUSIP 00BNRR5C1
1
institutional holders
1.4k
shares reported held*
$9.8kreported value*
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $7.16.
Biggest buyers
| Propel Bio Management, LLC | New | +1.4k |
Biggest sellers
| None |
Holders, Q2 2024
| Manager | Shares | Change |
|---|---|---|
| Propel Bio Management, LLC 0.01% of their portfolio | 1.4k $9.8k | New |